New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable 1-04-2025, 00:00

Social Media and Content Strategies for Black 18-02-2023, 00:28

TYLin Group Announces Strategic Leadership Appointment - Jenni Roseleip as Chief Marketing Officer 7-08-2025, 23:27